Donanemab Extension Study for Alzheimer's Disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the previous donanemab study (AACM Addendum 7)
- You must have a reliable study partner (caregiver) and a backup who knows your daily activities and memory
- You cannot be pregnant or of childbearing potential if assigned female at birth; males are eligible
- You cannot have serious or unstable medical conditions that would interfere with the study
- You cannot have brain imaging that shows certain abnormalities (like bleeding or structural problems)
- You cannot have metal implants or a pacemaker that prevents safe MRI scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a monthly infusion drug called donanemab, which aims to clear amyloid plaques (a hallmark of Alzheimer's) from the brain, potentially slowing memory decline in people with early Alzheimer's disease. Participants will receive the drug as part of this study.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.